Yüklüyor......
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially changed the treatment of lung cancer. First-line treatment with EGFR TKIs (gefitinib, erlotinib and afatinib) has demonstrated a s...
Kaydedildi:
| Yayımlandı: | Ther Adv Med Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5349427/ https://ncbi.nlm.nih.gov/pubmed/28344665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016687262 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|